Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNS-314 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose escalating cohorts of SNS-314 | EXPERIMENTAL | Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema. |
| Name | Type | Description |
|---|---|---|
| SNS-314 | DRUG | Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15 Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1 |
Inclusion Criteria: * Advanced solid tumor and that is measurable by a scan Exclusion Criteria: * Uncontrolled or untreated central nervous system metastases * Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1 * Any of the following cardiac conditions: * Histo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SNS-314 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, and a completed trial evaluated its safety and tolerability in patients with advanced solid tumors.
SNS-314 is being developed by Viracta Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VIRX. The company is conducting clinical research to evaluate the drug's potential in oncology.
SNS-314 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational, meaning it has not been approved by regulatory authorities and is still undergoing clinical evaluation.
SNS-314 has been studied in one clinical trial, identified as NCT00519662. This Phase 1 study, titled 'Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors,' was completed and enrolled 32 participants in the United States.
SNS-314 is the primary name used for this investigational drug. No alternative names have been reported in clinical trial records, and it is identified solely as SNS-314 in the context of its development by Viracta Therapeutics.